A team led by researchers at George Mason University has completed a phosphoproteomic analysis of the National Cancer Institute-60, a set of 60 human cancer cell lines.

The analysis provides a means of linking protein pathway activation information to other data generated via study of the NCI-60 set, including data from previous omics experiments and drug-sensitivity studies, said Emanuel Petricoin, co-director of GMU's Center for Applied Proteomics and Molecular Medicine and one of the leaders of the effort.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.